Publications by authors named "Zeming Mo"

Claim this Profile
C
Case Report: Ivonescimab in EGFR-mutant lung cancer with baseline malignant pleural effusion and acquired complex resistance.
Zeming Mo, Honglian Jiang, Lei Zhou, Qiaoya Ren, Gang Shen

Front Immunol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Melanoma: Pathogenesis and Targeted Therapy.
Yang Fu, Jie Liu, Zeming Mo, Bin Wang, Yaotiao Deng

MedComm (2020)· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KC1036, a multi-kinase inhibitor with anti-angiogenic activity, can effectively suppress the tumor growth of Ewing sarcoma.
Xuejin Ou, Ge Gao, Qizhi Ma, Diyuan Qin, Kai Li, Zeming Mo

Angiogenesis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global trends in tertiary lymphoid structures: a bibliometric analysis from 2014 to 2023.
Yiwen Bao, Zeming Mo, Shuang Wang, Jinhua Long, Honghong Zhang

Front Immunol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacies of anlotinib monotherapy versus gemcitabine-based chemotherapy for patients with advanced soft tissue sarcoma after the failure of anthracycline-based chemotherapy.
Aiping Zheng, Jie Liu, Zijing Liu, Zeming Mo, Yang Fu

J Cancer Res Clin Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS).
Yiwen Bao, Jiaju Chen, Luting Duan, Fujue Wang, Han Lai, Zeming Mo

Front Pharmacol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of cardiotoxicity of anthracycline-containing chemotherapy regimens in patients with bone and soft tissue sarcomas: A study of the FDA adverse event reporting system joint single-center real-world experience.
Zeming Mo, Yaotiao Deng, Yiwen Bao, Jie Liu, Yu Jiang

Cancer Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of NRAS mutations and tertiary lymphoid structure formation with clinical outcomes of adjuvant PD-1 inhibitors for acral melanoma.
Zeming Mo, Jie Liu, Jinyan Zhang, Yaotiao Deng, Miao Xu

Int Immunopharmacol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis.
Qizhi Ma, Xia He, Benxia Zhang, Fuchun Guo, Xuejin Ou, Zeming Mo

Signal Transduct Target Ther· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-Dose Radiation Therapy Promotes Radiation Pneumonitis by Activating NLRP3 Inflammasome.
Xiaoyu Li, Youling Gong, Dan Li, Li Xiang, Yuhong Ou, Zeming Mo

Int J Radiat Oncol Biol Phys· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[The Construction of ROR1 Targeting Chimeric Antigen Receptor Modified T Cells and Its Killing Effect for ROR1-positive Tumor Cells].
Yue Chen, Ze-Ming Mo, Di-Yuan Qin, Fu-Chun Guo, Xue-Lian Liao

Sichuan Da Xue Xue Bao Yi Xue Ban· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells.
Zeming Mo, Peixin Du, Guoping Wang, Yongsheng Wang

J Cancer· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Malignant Pleural Effusion and ascites Induce Epithelial-Mesenchymal Transition and Cancer Stem-like Cell Properties via the Vascular Endothelial Growth Factor (VEGF)/Phosphatidylinositol 3-Kinase (PI3K)/Akt/Mechanistic Target of Rapamycin (mTOR) Pathway.
Tao Yin, Guoping Wang, Sisi He, Guobo Shen, Chao Su, Zeming Mo

J Biol Chem· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Bing-Lan Zhang, Di-Yuan Qin, Ze-Ming Mo, Yi Li, Wei Wei

Sci China Life Sci· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis.
Binglan Zhang, Zeming Mo, Wei Du, Yan Wang, Lei Liu

Oral Oncol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis